Loading organizations...
Peregrine Capital operates as a specialized hedge fund manager, providing investment vehicles designed for wealth protection and growth. The firm offers distinct strategies, including a Pure Hedge Fund focused on stable, protected investments with above-inflation returns, and a High Growth Fund engineered for long-term wealth creation through strategic investment in equity and diverse assets. Its investment approach emphasizes active management and diversification, aiming to generate risk-adjusted returns and downside protection across various market conditions, independent of broad stock market performance.
The company commenced its operations in 1998, establishing itself as South Africa's longest-running hedge fund manager. Peregrine Capital was founded on the insight that robust hedge fund management could consistently protect and grow client wealth through disciplined investment practices. This foundational belief has guided its methodology, which seeks to defy conventional investment limitations by harnessing the power of diversification and strategic asset allocation to deliver consistent financial results.
Peregrine Capital serves a clientele of investors seeking sophisticated solutions for safeguarding and expanding their capital. Its overarching vision is to transform traditional perceptions of investment, enabling clients to unlock superior returns while diligently protecting their assets. The firm commits to a legacy of exceptional performance, striving to deliver consistent, inflation-beating results and long-term financial security for its investors.
Peregrine Investments has 1 tracked investment across 1 company. The latest tracked deal is $22.0M Series C in Raziel Therapeutics in December 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 1, 2019 | Raziel Therapeutics | $22.0M Series C | Pontifax | Catalyst Fund, Docor International Management, Karimah ES Sabar, Wille Finance |